Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

sylvain carlioz stimunity immunooncology2

News and Trends 5 Sep 2016

This Parisian Biotech Startup wants to clear a Major Hurdle in Immuno-oncology

Immuno-oncology is definitely the most promising breakthrough in cancer research right now. But the main issue is  that only 20-30% of patients respond to this therapy because of a weak immune system. I met Sylvain Carlioz, the co-founder of Stimunity, who wants to solve that problem. Carlioz was working at the tech transfer office of […]

September 5, 2016 - 4 minutesmins - By Philip Hemme

Screen Shot 2016 09 02 at 17.01.35

News and Trends 3 Sep 2016

Mouths & their Microbiomes Grow in this London Bioart Exhibit

Anna Dumitriu’s microbial art is at once revolting and captivating. She is showcasing her latest collaborative work on mouth bacteria at the Science Gallery London. Anna Dumitriu is a UK-based bioartist fascinated by the human microbiome: she creates art to express our relationships with the communities we host. We checked in on her earlier this year […]

September 3, 2016 - 3 minutesmins - By Evelyn Warner

8371216581 894034914a k

News and Trends 2 Sep 2016

Roche rockets into Checkpoint Inhibitor space with Phase III Lung Cancer Success

Tecentriq could be Roche’s ticket to the top of immuno-oncology. The checkpoint inhibitor just reached its co-primary endpoints in Phase III trials for non-small cell lung cancer and could bring the company €4.5B. Roche’s Tecentriq (atezolizumab) has demonstrated that it is a force to be reckoned with by clearing Phase III clinical trials for non-small cell […]

September 2, 2016 - 2 minutesmins - By Evelyn Warner

themis bioscene header

News and Trends 2 Sep 2016

Vienna-based Themis Bioscience frontlines vaccine development against emerging diseases

From Switzerland, we depart once again, this time for Vienna. This week, we are visiting Themis Bioscience, our Biotech of the Week (and also stopping for schnitzel). City: Vienna, Austria Founded: 2009 Employees: 4 Financial Data: €10M Total Raised (as of 12/2015) CEO: Erich Tauber Mission: Themis Bioscience targets emerging diseases, like Zika and Chikungunya, and aims to develop […]

September 2, 2016 - 1 minutemin - By Evelyn Warner

9207900897 ebbd71c424 k

News and Trends 2 Sep 2016

This €18M Joint Venture could Scale Up Bioplastic Film Production

Roughly 300 million tons of plastic are produced globally every year, but only 700 thousand tons are bio-based and biodegradable. Carbios’s new Joint Venture aims to dramatically grow this market. Carbios has announced the formation of CARBIOLICE, a new French joint venture shared between it, Limagrain Céréales Ingrédients (a heavyweight in the field of mulching films) […]

September 2, 2016 - 2 minutesmins - By Evelyn Warner

3745612739 6aae37ce01 b

News and Trends 1 Sep 2016

Infographic: How Cancer Starts & How It Chooses Organs

Here’s a neat infographic from Cancer Research UK summarizing a new Cell report from UK researchers that describes how conditions build to trigger cancer. This information would help to explain the greater vulnerability of certain organs to tumors compared to others. The team, headed by Richard James Gilbertson, demonstrated that while cells may start with equal carcinogenic risk, tumor […]

September 1, 2016 - 1 minutemin - By Evelyn Warner

ADVERTISEMENT

cevec nicole faust cap gt gene therapy

News and Trends 1 Sep 2016

Cevec: “Our Special Cell Lines will help the next generation of Gene Therapy”

Cevec could very well be the missing link between adenoviral vectors and approved gene therapies. I had a chat with the CSO of Cevec about what makes its technology great and how it’s ready for the future of gene therapy. Gene therapy is one of the strongest trends in biotechnology right now. The field has […]

September 1, 2016 - 6 minutesmins - By Denise Neves Gameiro

3245274082 b505b467bb o

News and Trends 1 Sep 2016

GSK is Advancing a Revolutionary Dual HIV Therapy

Gilead has long been the leader in HIV treatments, but GlaxoSmithKline’s CEO revealed to the WSJ that the company has been investing in the field. It could give Gilead a run for its money with dolutegravir, a new integrase inhibitor so powerful it may knock the standard down from triple to dual therapy. Since the […]

September 1, 2016 - 3 minutesmins - By Evelyn Warner

11321008994 657ec8f763 k 2

News and Trends 31 Aug 2016

Novartis’ second FDA Biosimilar Approval could unlock Billions

Novartis just attained FDA approval for a second biosimilar in the US. Erelzi will unlock the €4.5B rheumatoid arthritis market cornered by Enbrel. Sandoz, a division of Novartis based in the Munich area, has taken home another trophy from the biosimilar battleground by scoring a second FDA approval for its copycat, Erelzi (etanercept-szzs). This drug mimics Enbrel, a €4.5B franchise managed by Amgen in the US that treats rheumatoid arthritis as well […]

August 31, 2016 - 2 minutesmins - By Evelyn Warner

carmat artificial heart

News and Trends 31 Aug 2016

World’s most advanced Artificial Heart started its last Study before Approval

This artificial heart could replace any defective heart. It’s being developed by the French company Carmat, which just started the last clinical phase before market approval. Carmat is solving one of the life-long problems for humans, how to replace a broken heart. It’s not the first to offer a solution (e.g. Robert Jarvik in the US), […]

August 31, 2016 - 3 minutesmins - By Philip Hemme

2 eva lotta karin aiach philippe pouletty v2

News and Trends 31 Aug 2016

Discover the best Refresh Program we’ve ever made!

Hi there, I’m excited to show you what we have been cooking for our next Labiotech Refresh event in Paris on Nov 24th. We’ve been working hard on bringing in top-notch speakers to build up what we think is our most exciting program so far. Some of the highlights include a Keynote of French Biotech […]

August 31, 2016 - 1 minutemin - By Philip Hemme

5349367127 84887f37b1 o

News and Trends 31 Aug 2016

No Tumour, No Cancer Cure: New Epigenetic Test can pinpoint Elusive Ones

Not all tumours are detectable, which makes them particularly deadly. Researchers at the University of Barcelona have developed an epigenetic test to find them, the first of its kind to diagnose tumour sources. Cancer starts with a tumour, which grows and eventually sheds cells. These cells lodge in other tissues in the body and grow […]

August 31, 2016 - 3 minutesmins - By Evelyn Warner

ADVERTISEMENT